Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.76), $0.11 better than the analyst estimate of ($0.87). Revenue for the quarter came in at $12.37 million versus the consensus estimate of $8.14 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.